JP2020505403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505403A5 JP2020505403A5 JP2019540384A JP2019540384A JP2020505403A5 JP 2020505403 A5 JP2020505403 A5 JP 2020505403A5 JP 2019540384 A JP2019540384 A JP 2019540384A JP 2019540384 A JP2019540384 A JP 2019540384A JP 2020505403 A5 JP2020505403 A5 JP 2020505403A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- motomeko
- composition
- cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 239000000232 Lipid Bilayer Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 230000002159 abnormal effect Effects 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 4
- 210000004962 mammalian cell Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- GSHCNPAEDNETGJ-HKOLQMFGSA-N 2-[2,3-bis[[(z)-octadec-9-enoyl]oxy]propoxy-ethoxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(=O)(OCC)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC GSHCNPAEDNETGJ-HKOLQMFGSA-N 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- -1 antibodies Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000007771 core particle Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 210000002540 macrophage Anatomy 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 244000144972 livestock Species 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010050017 Lung cancer metastatic Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical group O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950006370 epacadostat Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 108700014844 flt3 ligand Proteins 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000034701 macropinocytosis Effects 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002353 niosome Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229940048914 protamine Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000011856 silicon-based particle Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022184788A JP7509504B2 (ja) | 2017-01-27 | 2022-11-18 | 免疫療法のためのコア／シェル構造プラットホーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451575P | 2017-01-27 | 2017-01-27 | |
| US62/451,575 | 2017-01-27 | ||
| PCT/US2018/015601 WO2018140826A1 (en) | 2017-01-27 | 2018-01-26 | Core/shell structure platform for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184788A Division JP7509504B2 (ja) | 2017-01-27 | 2022-11-18 | 免疫療法のためのコア／シェル構造プラットホーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505403A JP2020505403A (ja) | 2020-02-20 |
| JP2020505403A5 true JP2020505403A5 (enExample) | 2021-03-11 |
| JP7181880B2 JP7181880B2 (ja) | 2022-12-01 |
Family
ID=61899339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540384A Active JP7181880B2 (ja) | 2017-01-27 | 2018-01-26 | 免疫療法のためのコア／シェル構造プラットホーム |
| JP2022184788A Active JP7509504B2 (ja) | 2017-01-27 | 2022-11-18 | 免疫療法のためのコア／シェル構造プラットホーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022184788A Active JP7509504B2 (ja) | 2017-01-27 | 2022-11-18 | 免疫療法のためのコア／シェル構造プラットホーム |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11382964B2 (enExample) |
| EP (3) | EP4008344B1 (enExample) |
| JP (2) | JP7181880B2 (enExample) |
| KR (2) | KR102627347B1 (enExample) |
| CN (2) | CN109152830B (enExample) |
| AU (1) | AU2018212887B2 (enExample) |
| CA (1) | CA3051136A1 (enExample) |
| DK (2) | DK4008344T5 (enExample) |
| ES (2) | ES2973040T3 (enExample) |
| SG (1) | SG11201906744VA (enExample) |
| WO (1) | WO2018140826A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| AU2018269742B2 (en) * | 2017-05-18 | 2024-01-11 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| US20210170005A1 (en) * | 2018-08-15 | 2021-06-10 | University Of Florida Research Foundation, Inc. | Methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
| MA54192A (fr) * | 2018-11-07 | 2021-09-15 | Modernatx Inc | Vaccins à arn contre le cancer |
| CN109260157A (zh) * | 2018-11-19 | 2019-01-25 | 上海交通大学 | 一种正电荷多肽脂质体纳米制剂及其制备方法与应用 |
| CN113557035B (zh) * | 2019-01-12 | 2025-09-05 | 卫理公会医院 | 自组装肽纳米颗粒和其用途 |
| PH12021552218A1 (en) * | 2019-03-14 | 2022-05-30 | Engene Inc | Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| US20220307024A1 (en) * | 2019-06-17 | 2022-09-29 | Alnylam Pharmaceuticals, Inc. | Delivery of oligonucleotides to the striatum |
| CA3144902A1 (en) * | 2019-08-14 | 2022-01-19 | Andreas Thess | Rna combinations and compositions with decreased immunostimulatory properties |
| DE102019122014A1 (de) * | 2019-08-15 | 2021-02-18 | Technische Universität Darmstadt | Reduktion der Knochenresorption, insbesondere bei chronischen Gelenkerkrankungen |
| WO2021081043A1 (en) * | 2019-10-22 | 2021-04-29 | The Johns Hopkins University | Mucus penetrating particle compositions and methods of use thereof enhancing immune response |
| KR102579284B1 (ko) * | 2020-09-22 | 2023-09-18 | 비피진 주식회사 | 신규의 cd47 바인더와 폴리뉴클레오티드를 포함하는 암 치료를 위한 리포좀 복합체 |
| CN112245575B (zh) * | 2020-10-26 | 2024-07-26 | 上海杏禾医疗科技有限公司 | 含支化聚合物和mRNA的核壳结构的抗肿瘤疫苗及其用途 |
| WO2023034957A1 (en) * | 2021-09-03 | 2023-03-09 | University Of Connecticut | Stabilization of antigens for long term administration in transdermal microneedle patches |
| CN114699420A (zh) * | 2022-03-08 | 2022-07-05 | 南方科技大学 | 一种用于治疗前列腺癌组合物及其制备方法与应用 |
| CN114699538A (zh) * | 2022-04-02 | 2022-07-05 | 中国药科大学 | 一种核-壳式高效基因药物递送系统及其制备方法 |
| BE1031669B1 (fr) * | 2023-06-02 | 2025-01-14 | Inhatarget Therapeutics | Composition pharmaceutique pour inhalation |
| BE1031668B1 (fr) * | 2023-06-02 | 2025-01-16 | Inhatarget Therapeutics | Composition pharmaceutique pour inhalation |
| CN117045809B (zh) * | 2023-09-27 | 2025-08-29 | 国家纳米科学中心 | 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用 |
| KR20250063352A (ko) * | 2023-11-01 | 2025-05-08 | 가톨릭대학교 산학협력단 | mRNA가 봉입된 이중 나노입자, 이의 제조방법 및 이의 약학적 용도 |
| CN117442552B (zh) * | 2023-11-20 | 2024-03-26 | 山东大学 | 一种淋巴结内t细胞区靶向纳米粒及其水凝胶 |
| CN117883410A (zh) * | 2024-01-22 | 2024-04-16 | 华中科技大学同济医学院附属协和医院 | 包封有mRNA及Acod1基因si-RNA的脂质体纳米颗粒及其应用 |
| CN118001254B (zh) | 2024-04-09 | 2024-07-26 | 北京悦康科创医药科技股份有限公司 | 靶向抗原呈递细胞的脂质组合物及其应用 |
| DE102024112307A1 (de) * | 2024-05-02 | 2025-11-06 | INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung | Kompositpartikel |
| CN119040262B (zh) * | 2024-08-22 | 2025-11-18 | 北京理工大学 | 一种呈递肿瘤抗原并高度激活t细胞的外泌体通用制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| AU2012323937A1 (en) * | 2011-10-14 | 2014-06-05 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| CN103181896B (zh) * | 2011-12-30 | 2015-10-14 | 沈阳药科大学 | 一种含有小檗胺类药物的脂质体制剂及其制备方法 |
| WO2014153052A2 (en) * | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| CN103550783A (zh) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种核酸类药物靶向递送系统及其制备方法 |
| CN105555757A (zh) * | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
| BR112016008832A2 (pt) * | 2013-10-22 | 2017-10-03 | Shire Human Genetic Therapies | Distribuição de mrna no snc e suas utilizações |
| SG11201808671YA (en) * | 2015-04-02 | 2018-11-29 | Methodist Hospital | Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity |
| KR102579284B1 (ko) | 2020-09-22 | 2023-09-18 | 비피진 주식회사 | 신규의 cd47 바인더와 폴리뉴클레오티드를 포함하는 암 치료를 위한 리포좀 복합체 |
-
2018
- 2018-01-26 SG SG11201906744VA patent/SG11201906744VA/en unknown
- 2018-01-26 EP EP21210308.9A patent/EP4008344B1/en active Active
- 2018-01-26 DK DK21210308.9T patent/DK4008344T5/da active
- 2018-01-26 DK DK18715827.4T patent/DK3573656T3/da active
- 2018-01-26 ES ES21210308T patent/ES2973040T3/es active Active
- 2018-01-26 EP EP18715827.4A patent/EP3573656B1/en active Active
- 2018-01-26 JP JP2019540384A patent/JP7181880B2/ja active Active
- 2018-01-26 CN CN201880001680.5A patent/CN109152830B/zh active Active
- 2018-01-26 KR KR1020197024702A patent/KR102627347B1/ko active Active
- 2018-01-26 WO PCT/US2018/015601 patent/WO2018140826A1/en not_active Ceased
- 2018-01-26 CA CA3051136A patent/CA3051136A1/en active Pending
- 2018-01-26 US US15/881,637 patent/US11382964B2/en active Active
- 2018-01-26 KR KR1020247001662A patent/KR20240014586A/ko active Pending
- 2018-01-26 CN CN202310076857.0A patent/CN115845040A/zh active Pending
- 2018-01-26 EP EP23214393.3A patent/EP4309739A3/en active Pending
- 2018-01-26 ES ES18715827T patent/ES2905591T3/es active Active
- 2018-01-26 AU AU2018212887A patent/AU2018212887B2/en active Active
-
2022
- 2022-05-24 US US17/751,812 patent/US20220305103A1/en active Pending
- 2022-11-18 JP JP2022184788A patent/JP7509504B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505403A5 (enExample) | ||
| KR101839864B1 (ko) | 암을 치료하는 방법 | |
| JP2024133065A (ja) | メッセンジャーリボ核酸薬物の治療投与のための方法 | |
| US20200276230A1 (en) | Particles for the treatment of cancer in combination with radiotherapy | |
| Xu et al. | Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12 | |
| JP6240600B2 (ja) | ヒト化免疫モノクローナル抗体の変異体 | |
| US11433136B2 (en) | Polyacetal polymers, conjugates, particles and uses thereof | |
| WO2021098621A1 (zh) | 一种包载免疫佐剂纳米颗粒及应用 | |
| JP2023014340A (ja) | ポリマーナノ粒子 | |
| TWI873079B (zh) | 作為治療疫苗之奈米顆粒 | |
| WO2019213686A1 (en) | Therapeutic compositions and uses therefor | |
| CN107137717A (zh) | 一种携载抗肿瘤药物连接cd22单抗靶向淋巴瘤的血小板靶向载药体系的制备方法 | |
| EP4243778A1 (en) | Nanoparticle complex with defined sizes | |
| JP5843086B2 (ja) | 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用 | |
| JP2025523084A (ja) | ナノ粒子と放射性医薬品の併用療法 | |
| US20230381349A1 (en) | Methods and compositions for imaging and treating cancer | |
| WO2021239730A1 (en) | Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof | |
| Rajalakshmi et al. | Nanomedicine for Cancer Therapy: Current Status and Challenges | |
| JP6987271B2 (ja) | 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途 | |
| EP4031180A1 (en) | Methods for triggering m1 macrophage polarization | |
| Wang et al. | A Carrier-free Peptide Co-assembled System with Synergistic Antitumor Effect Combines Immunotherapy and Sonodynamic Therapy | |
| NL2027601B1 (en) | Target mediated endocytotic drug delivery | |
| NL2026569B1 (en) | Target mediated endocytotic drug delivery | |
| Rengan | 9 Nanomedicine for Cancer Therapy | |
| Dong et al. | Noninvasive ultrasound targeted modulation of calcium influx in splenic immunocytes potentiates antineoplastic immunity attenuating hepatocellular carcinoma proliferation |